pharma · severe uncontrolled asthma · mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD) · GENB
Generate Biomedicines
Generate Biomedicines is a pharma organization headquartered in Somerville, USA. It trades on NYSE under ticker GENB. Primary therapeutic focus areas include severe uncontrolled asthma, mild to moderate asthma, Chronic O
Somerville, USA HQ
325 Employees
Public company Type
GENB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Somerville, USA
- Employees
- 325
- Programs
- 8
- Drugs
- 7
- Patents
- 1
0.9% sodium chloride, GB-0895
Phase 3 · small molecule · severe uncontrolled asthma
0.9% sodium chloride, GB-0895 for severe uncontrolled asthma is a Phase 3 program (small_molecule) at Generate Biomedicines with 1 ClinicalTrials.gov record(s).
Internal code GB-0895-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Generate Biomedicines
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- severe uncontrolled asthma
- Status
- active
- Trials
- 1